Gallbladder Tumors Clinical Presentation

1. D'Hondt M, Lapointe R, Benamira Z, Pottel H, Plasse M, Letourneau R, et al. Carcinoma of the gallbladder: patterns of presentation, prognostic factors and survival rate. An 11-year single centre experience. Eur J Surg Oncol. 2013 Jun. 39 (6):548-53. [QxMD MEDLINE Link].

2. Blalock AA. A statistical study of 888 cases of biliary tract disease. Johns Hopkins Hospital Bulletin. 1924. 35:391-409.

3. Shirai Y, Yoshida K, Tsukada K, Ohtani T, Muto T. Identification of the regional lymphatic system of the gallbladder by vital staining. Br J Surg. 1992 Jul. 79 (7):659-62. [QxMD MEDLINE Link].

4. Tumors of the gallbladder. Jarnagin WR, Allen PJ, Chapman WC, D'Angelica MI, DeMatteo RP, Do RKG, et al, eds. Blumgart's Surgery of the Liver, Biliary Tract, and Pancreas. 7th ed. Philadelphia: Elsevier; 2022. Chap 49.

5. Kwon AH, Inui H, Matsui Y, Uchida Y, Hukui J, Kamiyama Y. Laparoscopic cholecystectomy in patients with porcelain gallbladder based on the preoperative ultrasound findings. Hepatogastroenterology. 2004 Jul-Aug. 51 (58):950-3. [QxMD MEDLINE Link].

6. Stephen AE, Berger DL. Carcinoma in the porcelain gallbladder: a relationship revisited. Surgery. 2001 Jun. 129 (6):699-703. [QxMD MEDLINE Link].

7. Chu H, Shi Y, Liu J, Huang D, Zhang J, Dou C. Update in clinical management for gallbladder neuroendocrine carcinoma. Medicine (Baltimore). 2021 Apr 9. 100 (14):e25449. [QxMD MEDLINE Link]. [Full Text].

8. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008 Feb 16. 371 (9612):569-78. [QxMD MEDLINE Link].

9. Key statistics for gallbladder cancer. American Cancer Society. Available at https://www.cancer.org/cancer/types/gallbladder-cancer/about/key-statistics.html. January 12, 2023; Accessed: May 31, 2023.

10. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review (CSR) 1975-2018. National Cancer Institute. Available at https://seer.cancer.gov/csr/1975_2018/. April 15, 2021; Accessed: May 31, 2023.

11. Shindoh J, de Aretxabala X, Aloia TA, Roa JC, Roa I, Zimmitti G, et al. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. Ann Surg. 2015 Apr. 261 (4):733-9. [QxMD MEDLINE Link].

12. Okada K, Kijima H, Imaizumi T, Hirabayashi K, Matsuyama M, Yazawa N, et al. Wall-invasion pattern correlates with survival of patients with gallbladder adenocarcinoma. Anticancer Res. 2009 Feb. 29 (2):685-91. [QxMD MEDLINE Link].

13. Li H, Yuan SL, Han ZZ, Huang J, Cui L, Jiang CQ, et al. Prognostic significance of the tumor-stroma ratio in gallbladder cancer. Neoplasma. 2017. 64 (4):588-593. [QxMD MEDLINE Link]. [Full Text].

14. Kim M, Kim H, Han Y, Sohn H, Kang JS, Kwon W, et al. Prognostic Value of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 19-9 (CA 19-9) in Gallbladder Cancer; 65 IU/mL of CA 19-9 Is the New Cut-Off Value for Prognosis. Cancers (Basel). 2021 Mar 4. 13 (5):[QxMD MEDLINE Link]. [Full Text].

15. Lv TR, Liu F, Liang ZY, Zou RQ, Ma WJ, Hu HJ, et al. Comparison of clinicopathological characteristics and long-term survival between patients with gallbladder adenosquamous carcinoma and pure gallbladder adenocarcinoma after curative-intent surgery: a single-center experience in China and a meta-analysis. Front Oncol. 2023. 13:1116275. [QxMD MEDLINE Link]. [Full Text].

16. Kong W, Zhang L, An R, Yang M, Wang H. Diagnostic Value of Serum D-Dimer for Detection of Gallbladder Carcinoma. Cancer Manag Res. 2021. 13:2549-2556. [QxMD MEDLINE Link]. [Full Text].

17. Okuyama Y, Fukui A, Enoki Y, Morishita H, Yoshida N, Fujimoto S. A large cell neuroendocrine carcinoma of the gall bladder: diagnosis with 18FDG-PET/CT-guided biliary cytology and treatment with combined chemotherapy achieved a long-term stable condition. Jpn J Clin Oncol. 2013 May. 43 (5):571-4. [QxMD MEDLINE Link].

18. Dehdashti F, Laforest R, Gao F, Shoghi KI, Aft RL, Nussenbaum B, et al. Assessment of cellular proliferation in tumors by PET using 18F-ISO-1. J Nucl Med. 2013 Mar. 54 (3):350-7. [QxMD MEDLINE Link].

19. Chun YJ, Jeung HC, Park HS, Park JS, Rha SY, Choi HJ, et al. Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured Using ¹⁸F-FDG PET/CT in Locally Advanced and Metastatic Gallbladder Carcinoma. Yonsei Med J. 2019 Jul. 60 (7):604-610. [QxMD MEDLINE Link]. [Full Text].

20. Gallbladder cancer treatment (PDQ®)–health professional version. National Cancer Institute. Available at https://www.cancer.gov/types/gallbladder/hp/gallbladder-treatment-pdq#section/_6. March 20, 2023; Accessed: May 31, 2023.

21. Zielinski MD, Atwell TD, Davis PW, Kendrick ML, Que FG. Comparison of surgically resected polypoid lesions of the gallbladder to their pre-operative ultrasound characteristics. J Gastrointest Surg. 2009 Jan. 13 (1):19-25. [QxMD MEDLINE Link].

22. Matsuyama R, Yabusita Y, Homma Y, Kumamoto T, Endo I. Essential updates 2019/2020: Surgical treatment of gallbladder cancer. Ann Gastroenterol Surg. 2021 Mar. 5 (2):152-161. [QxMD MEDLINE Link]. [Full Text].

23. Park JO, Oh DY, Hsu C, Chen JS, Chen LT, Orlando M, et al. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Res Treat. 2015 Jul. 47 (3):343-61. [QxMD MEDLINE Link].

24. Duffy A, Capanu M, Abou-Alfa GK, Huitzil D, Jarnagin W, Fong Y, et al. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol. 2008 Dec 1. 98 (7):485-9. [QxMD MEDLINE Link].

25. [Guideline] Biliary tract cancers. Version 2.2023. NCCN Clinical Practice Guidelines in Oncology™. Available at https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf. May 10, 2023; Accessed: May 31, 2023.

26. Mitin T, Enestvedt CK, Jemal A, Sineshaw HM. Limited Use of Adjuvant Therapy in Patients With Resected Gallbladder Cancer Despite a Strong Association With Survival. J Natl Cancer Inst. 2017 Jul 1. 109 (7):[QxMD MEDLINE Link].

27. [Guideline] Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, et al. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019 Apr 20. 37 (12):1015-1027. [QxMD MEDLINE Link]. [Full Text].

28. Zhou Y, Yuan K, Yang Y, Ji Z, Zhou D, Ouyang J, et al. Gallbladder cancer: current and future treatment options. Front Pharmacol. 2023. 14:1183619. [QxMD MEDLINE Link]. [Full Text].

29. Reddy SK, Clary BM. Surgical management of gallbladder cancer. Surg Oncol Clin N Am. 2009 Apr. 18 (2):307-24, ix. [QxMD MEDLINE Link].

30. [Guideline] Foley KG, Lahaye MJ, Thoeni RF, Soltes M, Dewhurst C, Barbu ST, et al. Management and follow-up of gallbladder polyps: updated joint guidelines between the ESGAR, EAES, EFISDS and ESGE. Eur Radiol. 2022 May. 32 (5):3358-3368. [QxMD MEDLINE Link]. [Full Text].

31. Wang Z, Li Y, Jiang W, Yan J, Dai J, Jiao B, et al. Simple Cholecystectomy Is Adequate for Patients With T1b Gallbladder Adenocarcinoma < 1 cm in Diameter. Front Oncol. 2019. 9:409. [QxMD MEDLINE Link]. [Full Text].

32. He XD, Li JJ, Liu W, Qu Q, Hong T, Xu XQ, et al. Surgical procedure determination based on tumor-node-metastasis staging of gallbladder cancer. World J Gastroenterol. 2015 Apr 21. 21 (15):4620-6. [QxMD MEDLINE Link].

33. Ito H, Ito K, D'Angelica M, Gonen M, Klimstra D, Allen P, et al. Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment. Ann Surg. 2011 Aug. 254 (2):320-5. [QxMD MEDLINE Link].

34. Tsilimigras DI, Hyer JM, Paredes AZ, Moris D, Beal EW, Merath K, et al. The optimal number of lymph nodes to evaluate among patients undergoing surgery for gallbladder cancer: Correlating the number of nodes removed with survival in 6531 patients. J Surg Oncol. 2019 Jun. 119 (8):1099-1107. [QxMD MEDLINE Link].

Thomas J VanderMeer, MD Assistant Professor of Surgery, State University of New York Upstate Medical University; Chief, Section of General Surgery, Program Director of General Surgery Residency Program, Guthrie Health System

Thomas J VanderMeer, MD is a member of the following medical societies: American College of Surgeons, American College of Surgeons Oncology Group, Americas Hepato-Pancreato-Biliary Association, Association for Surgical Education, Association of Program Directors in Surgery, Society for Surgery of the Alimentary Tract

Disclosure: Nothing to disclose.

Michael Kent McLeod, MD, MBA, FACE, FACS Associate Chair, Professor of Surgery and Program Director, Integrated General Surgery Program, Department of Surgery, Michigan State University College of Human Medicine

Michael Kent McLeod, MD, MBA, FACE, FACS is a member of the following medical societies: American Association of Clinical Endocrinologists, American Association of Endocrine Surgeons, American College of Surgeons, American Medical Association, Association for Academic Surgery, Central Surgical Association, International Association of Endocrine Surgeons, Michigan State Medical Society, Midwest Surgical Association, National Medical Association, Society of American Gastrointestinal and Endoscopic Surgeons, Western Surgical Association

Disclosure: Nothing to disclose.

Tara Mancl, MD Staff Physician, Department of Surgery, Michigan State University, Kalamazoo Center for Medical Studies

Tara Mancl, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Family Physicians, American College of Surgeons, American Medical Student Association/Foundation

Disclosure: Nothing to disclose.

Michel M Murr, MD Professor, Department of Surgery, Director of Bariatric Surgery, University of South Florida

Michel M Murr, MD is a member of the following medical societies: American College of Surgeons, Americas Hepato-Pancreato-Biliary Association, American Society for Metabolic and Bariatric Surgery, Association for Academic Surgery, International College of Surgeons US Section, Society for Surgery of the Alimentary Tract, Southeastern Surgical Congress

Disclosure: Received consulting fee from Covidien for consulting.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

John Geibel, MD, MSc, DSc, AGAF Vice Chair and Professor, Department of Surgery, Section of Gastrointestinal Medicine, Professor, Department of Cellular and Molecular Physiology, Yale University School of Medicine; Director of Surgical Research, Department of Surgery, Yale-New Haven Hospital; American Gastroenterological Association Fellow; Fellow of the Royal Society of Medicine

John Geibel, MD, MSc, DSc, AGAF is a member of the following medical societies: American Gastroenterological Association, American Physiological Society, American Society of Nephrology, Association for Academic Surgery, International Society of Nephrology, New York Academy of Sciences, Society for Surgery of the Alimentary Tract

Disclosure: Nothing to disclose.

Michael A Grosso, MD Consulting Staff, Department of Cardiothoracic Surgery, St Francis Hospital

Michael A Grosso, MD is a member of the following medical societies: American College of Surgeons, Society of Thoracic Surgeons, and Society of University Surgeons

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article